M&A

Johnson & Johnson Looks for New Deal That's Just Right
TheStreet.com
Thu, 12/15/16 - 12:16 pm
[video]JNJ
M&A
Actelion
Sanofi, Actelion Under Pressure for Deal After Past Failures
Bloomberg
Thu, 12/15/16 - 12:02 pm
Sanofi
Actelion
M&A
Actelion Would Be Second-Best Solution For Sanofi
Forbes
Wed, 12/14/16 - 09:22 am
Actelion
JNJ
Sanofi
M&A
Sanofi Said to Hold Talks With Actelion After J&J Walks Away
Bloomberg
Wed, 12/14/16 - 09:22 am
Sanofi
JNJ
Actelion
M&A
Actelion Shares Plunge After J&J Drops Potential $27 Billion Takeover
TheStreet.com
Wed, 12/14/16 - 09:21 am
Actelion
JNJ
M&A
Sanofi
Don't Buy The Depomed Buyout Rumors; Buy The Certainty Of An Eventual Deal
Seeking Alpha
Thu, 12/8/16 - 11:13 pm
Depomed
Novartis
M&A
Abbott Seeks To Terminate Alere Acquisition: 'Not The Company We Agreed To Buy'
Yahoo/Benzinga
Wed, 12/7/16 - 07:49 pm
Abbott Labs
Alere
M&A
Will Johnson & Johnson Take Over Actelion?
Investopedia
Wed, 12/7/16 - 07:47 pm
JNJ
Actelion
M&A
Sanofi
Terumo moves forward on $1B deal to pick up St. Jude, Abbott vascular assets
Mass Device
Wed, 12/7/16 - 07:42 pm
devices
Terumo
St. Jude Medical
Abbott Labs
M&A
Mylan eyes up to 3,500 layoffs in post-M&A cost-cutting drive
Fierce Pharma
Wed, 12/7/16 - 10:57 am
Mylan Labs
layoffs
M&A
Meda
Abbott Labs
Sanofi and Johnson & Johnson May Battle for the Right to Overpay for Actelion
Motley Fool
Wed, 12/7/16 - 10:44 am
JNJ
Sanofi
Actelion
M&A
Gilead Sciences Inc.'s Worst Moves in 2016
Motley Fool
Tue, 12/6/16 - 10:44 pm
Gilead Sciences
dividends
hepatitis C
M&A
Top Actelion shareholder says backs J&J deal above 246 Sfr/share
Yahoo/Reuters
Tue, 12/6/16 - 09:54 am
Actelion
JNJ
M&A
J&J Woos Billionaire Doctors Who Don’t Need Cash in Actelion Bid
Bloomberg
Tue, 12/6/16 - 09:52 am
JNJ
physicians
Actelion
M&A
Sanofi to Explore Counterbid for Actelion Amid J&J Talks
Bloomberg
Mon, 12/5/16 - 11:13 pm
Sanofi
Actelion
JNJ
M&A
Valeant: The Salix Sale Debacle
Seeking Alpha
Mon, 12/5/16 - 10:42 pm
Valeant Pharmaceuticals
Salix
M&A
Takeda
J&J's $26 Billion Swiss Drugs Experiment
Bloomberg
Mon, 12/5/16 - 10:07 am
JNJ
Switzerland
Actelion
M&A
PAH
What makes a PhII drug worth up to $665M? Researchers spell it out for Novartis
Endpoints
Mon, 12/5/16 - 09:48 am
Novartis
crizanlizumab
sickle cell disease
M&A
Selexys
Novartis CEO plays down prospects for Actelion bid
Yahoo/Reuters
Sun, 12/4/16 - 12:33 pm
Novartis
Actelion
M&A
Pharma CEOs
Joe Jimenez
Celgene buys Acetylon, keeps what it wants and spins the rest back out as Regenacy
Endpoints
Sat, 12/3/16 - 09:26 am
Celgene
Acetylon
M&A
Regenacy Pharmaceuticals

Pages